Immunohistochemical study of glypican 3 in thyroid cancer

Oncology

Volumn 73, Issue 5-6, 2008, Pages 389-394

  Yamanaka, Kanako ^a   Ito, Yasuhiro ^b   Okuyama, Noriko ^a   Noda, Katsuhisa ^a   Matsumoto, Hitoshi ^a   Yoshida, Hiroshi ^b   Miyauchi, Akira ^b   Capurro, Mariana ^c,d   Filmus, Jorge ^c,d   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMA HOSPITAL   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Glypican 3; Immunohistochemistry; Thyroid cancer

Indexed keywords

GLYPICAN 3;

ARTICLE; CANCER STAGING; CELL MEMBRANE; CONTROLLED STUDY; FOLLICULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER;

ADENOMA; CARCINOMA; CARCINOMA, PAPILLARY; GENE AMPLIFICATION; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM STAGING; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID GLAND; THYROID NEOPLASMS;

EID: 45549098512     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000136159     Document Type: Article

References (29)

1. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-777.
2. Filmus J, Selleck SB: Glypicans: proteoglycans with a surprise. J Clin Invest 1999;108:497-501.
3. Filmus J, Church J, Buick RN: Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol 1988;8:4243-4249.
4. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
5. Neri G, Gurrieri F, Zanni G, Lin A: Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79:279-283.
6. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Büchler MW: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
7. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-465.
8. Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M: Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003;94:259-262.
9. Capurro MI, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
10. Nakasura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y: Identification of glypican-3 as a novel marker for melanoma. Clin Cancer Res 2004;10:6612-6621.
11. Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, Komori H, Fukuma D, Baba H, Nishimura Y: Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006;66:2414-2422.
12. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006;12:2689-2697.
13. Faggin JA: Molecular genetics of tumors of thyroid follicular cells; in Braverman LE, Utiger RD (eds): The Thyroid, ed 8. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 886-898.
14. Metaye T, Kraimps JL, Goujon JM, Fernandez B, Quellard N, Ingrand P, Barbier J, Begon F: Expression, localization and thyrotropin regulation of cathepsin D in thyroid tissues. J Clin Endocrinol Metab 1997;82, 3383-3388.
15. Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.
16. Aratake Y, Kotani T, Tamura K, Araki Y, Kuribayashi T, Konoe K, Ohtaki S: Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases. Am J Clin Pathol 1991;96:306-310.
17. Sakamoto A, Kasai N, Sugano H: Poorly differentiated carcinoma of the thyroid. A clinicopathological entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983;52:1849-1855.
18. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
19. Filmus J: Glypicans in growth control and cancer. Glycobiology 2001;11:19R-23R.
20. Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR: Expression of GPC3 , an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000;19:410-416.
21. Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, Cappuro M, Brody JS, Lange J, D'Armiento JM, Rothman PB, Powell CA: The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 2003;29:694-701.
22. Xiang YY, Ladeda V, Filmus J: Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-7412.
23. Lin H, Huber R, Schlessinger D, Morin PJ: Frequent silencing of the GPC3 in ovarian cancer cell lines. Cancer Res 1999;59:807-810.
24. Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A, Kuribayashi T, Hirai K, Nabeshima K, Kotani T: Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002;26:336-372.
25. Lin X: Functions of heparan sulfate proteoglycans in cell signaling during development. Development 2004;131:6009-6021.
26. Song HH, Shi W, Xiang YY, Filmus J: The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005;280:2116-2125.
27. Capurro MI, Xiang YY, Lobe C, Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-6254.
28. Zhang L, David G, Esko JD: Repetitive Ser-Gly sequences enhance heparan sulfate assembly in proteoglycans. J Biol Chem 1995;270:27127-27135.
29. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D: Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996;12:241-247.